Abstract 2793: Design, synthesis and evaluations of novel class of orally bioavailable eIF4A3-selective inhibitors

Abstract

Eukaryotic initiation factor 4A3 (eIF4A3) is a member of the ATP-dependent RNA helicase protein family and controls RNA metabolism, including nonsense-mediated mRNA decay (NMD) and RNA localization, as a core component of the exon junction complex (EJC). Cancer cells often harbor a wide variety of mutations introducing PTCs, and cancer cells are thought to be highly dependent on the NMD pathway to avoid the accumulation of aberrant proteins. Therefore, targeting eIF4A3 inhibition could potentially represent a promising approach for anticancer therapy, however, the detailed physiological functions of eIF4A3 are not clear. To enable the further biological and pharmacological evaluation of eIF4A3, we recently discovered several classes of both ATP-competitive and allosteric eIF4A3 inhibitors which showed potent and selective eIF4A3 inhibition. Among these, the allosteric eIF4A3 inhibitors exhibited significant NMD inhibition in a cellular reporter assay along with eIF4A3 inhibitory potency and were examined for understanding the function of eIF4A3 in RNA homeostasis. Although the allosteric inhibitors showed potent enzymatic activity as well as cellular potency, the physicochemical properties such as solubility, metabolic stability, and pharmacokinetics were insufficient for conducting further biological and pharmacological studies. To identify improved probe molecules for the study of eIF4A3 function, we continued our chemistry efforts on allosteric inhibitors using the novel 3-(4-chlorophenyl)-1,4-diacylpiperazine derivative as a lead compound. Although many of them showed improved solubility and metabolic stability while maintaining eIF4A3 inhibitory potency, further testing indicated it to be a P-gp substrate. To address this issue, a pyridin-2(1H)-one derivative was prepared based on the calculated tPSA value for reducing polarity, which led us to the discovery of the novel class of orally bioavailable eIF4A3-selective inhibitors. Herein, we demonstrated their biological and pharmacological evaluations and showed anti-tumor efficacy without severe body weight loss in xenograft mice. Thus, our novel series of compounds represent promising tool compounds for the in vivo pharmacological study of selective eIF4A3 inhibition. Citation Format: Ryo Mizojiri, Daisuke Nakata, Yoshihiko Satoh, Daisuke Morishita, Sachio Shibata, Misa Iwatani-Yoshihara, Yohei Kosugi, Mai Kosaka, Junpei Takeda, Shigekazu Sasaki, Kazuaki Takami, Koichiro Fukuda, Masahiro Kamaura, Shinobu Sasaki, Ryosuke Arai, Douglas R. Cary, Yasuhiro Imaeda. Design, synthesis and evaluations of novel class of orally bioavailable eIF4A3-selective inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2793.